Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
暂无分享,去创建一个
Bruce D Cheson | Lawrence H Schwartz | Emanuele Zucca | Sally F Barrington | F. Cavalli | T. Lister | R. Fisher | L. Schwartz | B. Cheson | S. Barrington | E. Zucca | T Andrew Lister | Franco Cavalli | Richard I Fisher
[1] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Ioannidis,et al. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] T. Grogan,et al. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Raissaki,et al. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus , 1997, European Radiology.
[5] Bruce D Cheson,et al. Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Yasuhiko Sugawara,et al. Normal splenic volume in adults by computed tomography. , 2002, Hepato-gastroenterology.
[7] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Hindié,et al. 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[9] P. Kurtin,et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. , 2011, Blood.
[10] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[11] R. Reznek,et al. Spleen size: how well do linear ultrasound measurements correlate with three-dimensional CT volume assessments? , 2002, The British journal of radiology.
[12] J. Ioannidis,et al. 18 F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: , 2005 .
[13] S. Srisajjakul,et al. Normal Splenic Volume Assessment on CT in 426 Adults , 2012 .
[14] R. Hustinx,et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] R. Hicks,et al. FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ON STAGING AND MANAGEMENT OF EARLY-STAGE FOLLICULAR NON-HODGKIN LYMPHOMA , 2022 .
[16] M. Peters. A Study of Survivals in Hodgkin's Disease Treated Radiologically , 1950 .
[17] T. Kwee,et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[18] S. Reske,et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[20] A. LaCasce,et al. Interim [ 18 F ] fl uorodeoxyglucose positron emission tomography imaging in stage I – II non-bulky Hodgkin lymphoma : would using combined positron emission tomography and computed tomography criteria better predict response than each test alone ? , 2012 .
[21] Rosenberg Sa. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977 .
[22] J. S. Júnior,et al. 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma , 2010, The Journal of Nuclear Medicine.
[23] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[24] R. Fisher,et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[26] P. Gaulard,et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[27] M. Gönen,et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. Kojima,et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. , 2007, Cancer.
[29] S. Barrington,et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. , 2013, Blood.
[30] M. Mohty,et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[31] S. Pileri,et al. Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma , 2009 .
[32] G. Bisi,et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[33] G. Salles,et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[35] S. Hain,et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Y. Erdi,et al. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .
[37] A. Zelenetz,et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] H. Amthauer,et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.
[39] Muneeb Ahmed,et al. Determination of splenomegaly by CT: is there a place for a single measurement? , 2005, AJR. American journal of roentgenology.
[40] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Andrew Homb,et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.
[42] J. Byrd,et al. Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines , 2012 .
[43] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[44] O. Hoekstra,et al. On the Added Value of Baseline FDG-PET in Malignant Lymphoma , 2009, Molecular Imaging and Biology.
[45] S. Rosenberg. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977, Cancer treatment reports.
[46] J. Byrd,et al. Non-Hodgkin's Lymphomas, version 3.2012. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[47] J. C. Meneghetti,et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] B. Cheson. Hodgkin lymphoma: protecting the victims of our success. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Ash A. Alizadeh,et al. Utility of positron emission tomography scans in mantle cell lymphoma , 2011, American journal of hematology.
[52] H. Amthauer,et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. , 2014, Journal of Clinical Oncology.
[53] C. Copie-Bergman,et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] O. Casasnovas,et al. In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy , 2013, The Journal of Nuclear Medicine.
[55] J. Jagannathan,et al. Spleen in haematological malignancies: spectrum of imaging findings. , 2012, The British journal of radiology.
[56] J. Vose,et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] J. Radford,et al. Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] R. Houot,et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[59] V. Devita,et al. Report of the Committee on Hodgkin's Disease Staging Procedures. , 1971, Cancer research.
[60] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] S. Ferrero,et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.
[62] C. Metreweli,et al. Sonographic measurement of splenic length: Correlation with measurement at autopsy , 1999, Journal of clinical ultrasound : JCU.
[63] P. Marsden,et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] J Nucl Med , 2010 .
[65] J. Armitage,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Stephane Chauvie,et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.
[67] G. Salles,et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] T. Lister,et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Ora Israel,et al. 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.
[70] E. Kimby,et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[71] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[73] U. Jaeger,et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.
[74] M. Bøgsted,et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.